TransMedics Group, Inc. (NASDAQ: TMDX) is a Healthcare company (Medical - Devices) with a market capitalization of $3.3B. The Maz Rating grades it against the other companies in its sector.
TransMedics Group, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $93.91, TransMedics Group, Inc. trades at 22.2x trailing earnings, 4.5x sales and 5.9x book value, with an EV/EBITDA of 26.1. Over the last twelve months it generated about $732M of revenue and $147M of net income. It runs a gross margin of 58.6%, an operating margin of 11.9% and a net margin of 19.9%. It shows return on equity of 28.4%, return on invested capital of 6.1% and a free cash flow yield of 1.4%. On the balance sheet: a debt-to-equity ratio of 1.57 and a current ratio of 4.53. Over the past 52 weeks the share price ranged from $60.10 to $156.00, with a beta of 2.10.
TransMedics Group, Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 9 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, TransMedics Group, Inc. (TMDX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 17.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 17.2% / 30% · Interest income / Revenue 1.67% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 17.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 17.2% / 33% · Receivables / Mkt Cap (36m) 4.02% / 49% · Interest income / Revenue 1.67% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 17.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 17.2% / 33.33% · Receivables / Mkt Cap (24m) 4.02% / 33.33% · Interest income / Revenue 1.67% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 36.6% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 34.9% / 33.33% · Receivables / Avg Assets (4Q) 7.18% / 33.33% · Interest income / Revenue 1.67% / 5% | Fail |
| FTSE | Debt / Total Assets 33.6% / 33.33% · (Cash+ST Inv) / Total Assets 32.5% / 33.33% · (Cash+Recv) / Total Assets 40.0% / 33.33% · Interest income / Revenue 1.67% / 5% | Fail |
It depends on the standard you follow. As of September 2026, TransMedics Group, Inc. (TMDX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. TransMedics Group, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.67% of each dividend: TransMedics Group, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.